At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed May 29, 2026 at 08:00 ET
Replimune announced alignment with the FDA on a path forward for resubmission of the RP1 BLA for advanced melanoma, with the FDA committing to prioritize review. This is a significant regulatory de-risking event for a clinical-stage biotech with no approved products, transforming the company's outlook.
- Replimune and FDA aligned on path forward for RP1 BLA resubmission for advanced melanoma
- BLA resubmission expected in coming days; FDA will treat as urgent matter and prioritize review
- RP1 is Replimune's lead product candidate; company has no approved products
- Approximately 8,500 advanced melanoma deaths annually; ~50% of patients fail checkpoint inhibitor therapy
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access